Treating asthma with NIOX MINO® offers cost savings for the UK healthcare system

Treating asthma with NIOX MINO® offers cost savings for the UK healthcare system

SOLNA, Sweden, 12 February 2009 - Aerocrine AB (OMX Nordic Exchange: AERO) has
reported the recent publication of a UK study evaluating the effect of routine
inflammation measurement in asthma.

The economic study was intended to evaluate the effect on the direct costs of UK
asthma care when buying and using Aerocrine's NIOX MINO product.

By measuring inflammation - the underlying cause of asthma symptoms - doctor and
patient gain a better understanding of the symptom profile, and can control
treatment more optimally. The patient performs a simple exhaled air test into
the NIOX MINO, which returns an inflammation value. The study is based on
reimbursement of £23 per test from the NHS to care providers.

Results demonstrate that routine measurement in patients that use cortisone
inhaler generates a cost saving of £341 per patient and year. For sufferers of
more severe asthma, the saving is £554 per patient and year.
 
The savings are possible because treatment can be optimised using the results
from NIOX MINO tests. This reduces the number of visits to casualty and hospital
admissions, and cuts the amount of cortisone inhaler doses needed to keep
patients symptom free.

Thus, the introduction of continuous inflammation monitoring not only outweighs
the cost of testing with NIOX MINO, but also cuts the total cost of care.

The article was published in the latest issue of Allergy journal.
 
“The fact that measuring inflammation cuts healthcare costs while dramatically
improving control is highly significant for people that live with asthma and for
the UK healthcare system,” commented Paul de Potocki, CEO of Aerocrine.

For more information, please contact:

Paul de Potocki, CEO, tel: +46 (0)8 629 0782


About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in the technology to monitor and manage airway inflammation, Aerocrine
markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
11.30 am on 12 February 2009.